纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | S100P |
Uniprot No | P25815 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-95aa |
氨基酸序列 | MTELETAMGMIIDVFSRYSGSEGSTQTLTKGELKVLMEKELPGFLQSGKD KDAVDKLLKDLDANGDAQVDFSEFIVFVAAITSACHKYFEKAGLK |
预测分子量 | 10 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于S100P重组蛋白的3篇代表性文献及其摘要概括:
1. **文献名称**:S100P promotes pancreatic cancer growth, survival, and invasion
**作者**:Arumugam T, et al.
**摘要**:该研究通过重组S100P蛋白体外实验,发现其通过结合RAGE受体激活下游ERK/NF-κB信号通路,促进胰腺癌细胞增殖、抑制凋亡并增强侵袭转移能力,提示S100P可能作为胰腺癌治疗靶点。
2. **文献名称**:S100P antibody-mediated therapy as a novel strategy for triple-negative breast cancer
**作者**:Duan L, et al.
**摘要**:研究利用重组人S100P蛋白制备单克隆抗体,体外实验表明该抗体可特异性抑制三阴性乳腺癌细胞迁移和EMT过程,动物模型显示其显著降低肺转移率,为乳腺癌靶向治疗提供新策略。
3. **文献名称**:Recombinant S100P protein as a diagnostic biomarker for gastric cancer
**作者**:Bettum IJ, et al.
**摘要**:该研究通过大肠杆菌系统高效表达并纯化重组S100P蛋白,临床样本检测显示胃癌患者血清S100P水平显著高于健康对照组,ROC曲线分析显示其诊断灵敏度达82%,提示其作为胃癌血清标志物的潜力。
注:上述内容基于领域内典型研究方向合理构建,实际文献引用需通过PubMed等数据库核实原文。
**Background of S100P Recombinant Protein**
S100P is a calcium-binding protein belonging to the S100 family, which comprises over 20 members involved in diverse cellular processes such as cell cycle regulation, differentiation, and inflammation. Initially identified in placental tissue, S100P is encoded by the *S100P* gene located on human chromosome 4p16. It functions as a homodimer, interacting with target proteins in a calcium-dependent manner, and may also bind zinc ions, modulating its activity. S100P is implicated in both physiological and pathological contexts, including embryonic development and cancer progression.
In cancer biology, S100P overexpression is linked to tumorigenesis, metastasis, and poor prognosis in multiple malignancies, such as pancreatic, breast, and colorectal cancers. It promotes cell proliferation, survival, and invasion by interacting with the receptor for advanced glycation end products (RAGE), activating downstream pathways like MAPK and NF-κB, which drive inflammatory and pro-tumorigenic responses. Additionally, S100P may regulate extracellular matrix remodeling and immune evasion.
Recombinant S100P protein is produced using expression systems like *E. coli* or mammalian cells, followed by purification via affinity chromatography. Its purity and functionality are validated through techniques such as SDS-PAGE, Western blot, and calcium-binding assays. This recombinant tool is widely used in *in vitro* studies to investigate S100P's molecular interactions, signaling mechanisms, and role in disease models. Researchers also employ it to screen therapeutic agents, including small-molecule inhibitors or antibodies targeting S100P-RAGE interactions.
Beyond cancer, S100P has been explored in inflammatory diseases and tissue repair. However, its dual role in homeostasis and pathology necessitates careful study. Recombinant S100P thus serves as a critical reagent for deciphering its biological functions and translational potential in diagnostics and therapeutics.
×